10 completed, 1 active not recruiting. 4 Phase 1, 4 Phase 2, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 4 | Completed 3, Active not recruiting 1 |
| Not applicable | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Vicore Pharma AB: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. Buloxibutid, Placebo - Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Active not recruiting | Vicore Pharma AB | 378 | 2024-12-09 | 2026-08-17 |
| A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes C21 - Type2diabetes, Endothelial Dysfunction | Phase 1 | Completed | Vicore Pharma AB | 11 | 2023-03-31 | 2024-11-12 |
| A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers Drug Drug Interaction - Drug Interaction | Phase 1 | Completed | Vicore Pharma AB | 19 | 2023-03-29 | 2025-01-03 |
| First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects C106 solution, Placebo - Safety Issues, Tolerance | Phase 1 | Completed | Vicore Pharma AB | 80 | 2022-06-08 | 2025-01-31 |
| Effect of C21 on Forearm Blood Flow C21, Sodium Nitroprusside - Study Vasodilatory Effects of C21 | Phase 1 | Completed | Vicore Pharma AB | 5 | 2022-04-28 | 2025-04-23 |
| Controlled Investigation to Evaluate Impact of dCBT on Psychological Symptom Burden in Adult Subjects With PF Digital cognitive behavioral therapy - Pulmonary Fibrosis, Anxiety | Not applicable | Completed | Vicore Pharma AB | 119 | 2022-04-17 | 2024-09-24 |
| A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects C21, Placebo - COVID-19 | Phase 3 | Completed | Vicore Pharma AB | 272 | 2021-09-16 | 2023-12-14 |
| Retrospective Evaluation of Lung Pathology in Subjects With COVID-19 C21, Placebo - COVID-19, COVID-19 Pneumonia | Completed | Vicore Pharma AB | 35 | 2021-07-07 | 2024-09-04 | |
| Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF C21 - Idiopathic Pulmonary Fibrosis | Phase 2 | Completed | Vicore Pharma AB | 52 | 2020-11-13 | 2025-05-23 |
| Safety and Efficacy of C21 in Subjects With COVID-19 C21, Placebo - COVID-19 | Phase 2 | Completed | Vicore Pharma AB | 206 | 2020-07-21 | 2021-06-23 |
| Cold Challenge With C21 in RP C21, Placebo - Raynaud Phenomenon, Systemic Sclerosis | Phase 2 | Completed | Vicore Pharma AB | 20 | 2020-01-03 | 2023-05-18 |
COVID-19 (3) · Idiopathic Pulmonary Fibrosis (3) · Anxiety Disorders (1) · Hypertension, Pulmonary (1) · Pulmonary Fibrosis (1) · Raynaud Disease (1) · Scleroderma, Systemic (1)
compound 21 (8) · Caffeine (1) · Drug Interactions (1) · Midazolam (1) · Nitroprusside (1) · Tolbutamide (1) · nintedanib (1)
India (4) · Sweden (4) · United Kingdom (4) · United States (3) · Argentina (2) · Russia (2) · Ukraine (2) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · Colombia (1) · Czechia (1) · Germany (1)
Joanna Porter, MD (2) · Maureen Horton, MD (2) · Ariane Herrick, MD (1) · Helena Litorp, MD, PhD (1) · Rohit Batta, MD (1)
PMID 35894657, PMID 38344891, PMID 39627155
2019 (1), 2023 (1)